Clinical utility of cell-free DNA for the detection of ALK fusions and genomic mechanisms of ALK inhibitor resistance in non-small cell lung cancer.

CONCLUSIONS: In this cohort of cfDNA detected ALK fusions, we demonstrate that comprehensive cfDNA NGS provides a non-invasive means of detecting targetable alterations, and characterizing resistance mechanisms on progression.
PMID: 29599410 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - March 29, 2018 Category: Cancer & Oncology Authors: McCoach CE, Blakely CM, Banks KC, Levy BM, Chue B, Raymond VM, Le A, Lee CE, Diaz J, Waqar SN, Purcell WT, Aisner DL, Davies KD, Lanman RB, Shaw AT, Doebele RC Tags: Clin Cancer Res Source Type: research